Remedium Lifecare Ltd (SUPHA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Remedium Lifecare Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30 of SEBI (LODR), 2015
Others (Uncategorized) · 30 Jun 2026, 9:23 pm
NCLAT Restricts CoC Vote & Asset Sale Amid Related Party Dispute The NCLAT, in its order dated 22nd May'26, disposed of an appeal by Medec Infra Private Limited against its exclusion from Supha Pharmachem's Committee of Creditors (CoC) as a related party. While declining to entertain the appeal as the matter is listed before the Adjudicating Authority on 29th Jun'26, the NCLAT has granted interim protection. Until 29th Jun'26, it has directed that the CoC shall not vote on any resolution plan and has prohibited the sale of any immovable property of the corporate debtor.
Appointment of Resolution Professional in place of Interim Resolution Professional
Others (Uncategorized) · 12 May 2026, 8:38 pm
Supha Pharmachem Appoints New Resolution Professional During Insolvency Proceedings Supha Pharmachem Limited (formerly Remedium Lifecare) announced the NCLT-approved appointment of Mr. Raju Mangilal Marshiya as the new Resolution Professional (RP), effective from the order date of 30 Apr'26. This replaces the Interim Resolution Professional (IRP) as part of the ongoing Corporate Insolvency Resolution Process (CIRP). The appointment was approved by the Committee of Creditors (CoC) with a 67.28% voting share. Consequently, the Board of Directors' powers remain suspended, vesting with the newly appointed RP.
Disclosure to take note of decisions taken in 1st COC meeting held on 14.04.2026
Others (Uncategorized) · 18 Apr 2026, 3:19 am
Supha Pharmachem: CoC Appoints New Resolution Professional Amidst Insolvency Supha Pharmachem, currently under CIRP since 17 Mar'26, disclosed outcomes from its first Committee of Creditors (CoC) meeting. The CoC approved appointing Raju Mangilal Marshiya as the new Resolution Professional (RP), replacing the Interim RP. The former directors, whose powers are suspended, have been non-cooperative, failing to hand over company control and records. The RP is taking steps to seek cooperation and address pending non-compliances. The CoC also ratified IRP remuneration and approved the estimated budget for the next six months.
This disclosure is to place on record List of Creditors as required to be placed under Reg 13(2)(c) of IBBI CIRP Regulations
Others (Uncategorized) · 11 Apr 2026, 12:25 am
Supha Pharmachem: Creditor Claims Exceed Rs 1.23 Bn Amidst Insolvency Proceedings Supha Pharmachem, under CIRP since 17-Mar'26, disclosed total creditor claims of Rs 1,237.5 mn as of 06-Apr'26. Of this, Rs 821.7 mn has been admitted, Rs 3.8 mn is contingent, and Rs 411.9 mn remains under verification. The Interim Resolution Professional (IRP) reported non-cooperation from the suspended Board of Directors, who have failed to hand over control and records. The first Committee of Creditors (CoC) meeting is scheduled for 14-Apr'26 to appoint a Resolution Professional.
Update on CIRP Proceedings, Non-Cooperation by Directors (Power suspended) and Postponement of Board Meeting under Regulation 30 of SEBI (LODR) Regulation, 2015
Others (Uncategorized) · 02 Apr 2026, 11:49 pm
Supha Pharmachem Board Meeting Postponed Amid Insolvency and Director Non-Cooperation Supha Pharmachem's Board Meeting, scheduled for 30 Mar'26 to approve Q3 & 9M FY26 results, was postponed. The Interim Resolution Professional (IRP), appointed on 17 Mar'26 following the start of Corporate Insolvency Resolution Process (CIRP), cited non-cooperation from the suspended Board of Directors. The former directors have failed to hand over control, records, and financial information to the IRP, making it impossible to hold the meeting and approve the financials. This follows the NCLT's order dated 17 Mar'26 initiating CIRP.
Intimation of receipt of Order from National Company Law Tribunal (NCLT)
Others (Uncategorized) · 21 Mar 2026, 11:30 pm
Remedium Lifecare Admitted Into Insolvency Proceedings Over Unpaid Operational Debt The Mumbai NCLT admitted Remedium Lifecare into the Corporate Insolvency Resolution Process (CIRP) on 17 Mar'26. The petition was filed by operational creditor Boston Ivy Healthcare over a default of Rs 7.47 crore (Rs 6.19 crore principal plus interest) with the default date recorded as 07 Nov'23. Remedium Lifecare admitted the debt and requested admission into CIRP. The NCLT has appointed Mr. Rajesh Jhunjhunwala as the Interim Resolution Professional and declared a moratorium on the company's assets and legal proceedings.
Submission of Form A - PUBLIC ANNOUNCEMENT
Others (Uncategorized) · 21 Mar 2026, 4:11 am
Supha Pharmachem Enters Corporate Insolvency Resolution Process (CIRP) Supha Pharmachem Limited (formerly Remedium Lifecare) has entered the Corporate Insolvency Resolution Process (CIRP) following an order from the NCLT Mumbai Bench. The insolvency commencement date is 17th Mar'26. A public announcement inviting claims from creditors was made on 18th Mar'26, with a final submission deadline of 31st Mar'26. Mr. Rajesh Jhunjhunwala has been appointed as the Interim Resolution Professional (IRP) to oversee the process. The estimated closure date for the insolvency resolution process is 13th Sep'26.
Intimation for Admission of Co. under CIRP and appointment of IRP
Others (Uncategorized) · 19 Mar 2026, 11:59 pm
Supha Pharmachem Admitted into Corporate Insolvency Resolution Process (CIRP) Supha Pharmachem Ltd (formerly Remedium Lifecare) has been admitted into CIRP by the NCLT, Mumbai Bench, effective 17th Mar'26. The insolvency application was filed by operational creditor Boston Ivy Healthcare Solution for a default of Rs. 7.47 crore, which occurred on 07th Nov'23. A moratorium has been declared, prohibiting lawsuits and asset transfers. The Board of Directors' powers are suspended and vested with the Interim Resolution Professional, Mr. Rajesh Jhunjhunwala. This action severely impacts shareholder equity and company control.
Intimation of change in registered office of the company to office no. F81D, Express Zone Mall, A wing Next to Patel Vanika, W.E. Highway, Goregaon, (East), Mumbai - 400063, w.e.f. 17th ....
Others (Uncategorized) · 17 Mar 2026, 4:21 pm
Supha Pharmachem Announces Registered Office Relocation Supha Pharmachem (BSE: 539561) announced its Board of Directors approved the relocation of its registered office on 17th Mar'26. The company will shift from its current location at K Raheja Prime, Andheri (E), Mumbai, to a new office at Express Zone Mall, Goregaon (East), Mumbai. The change is effective from 17th Mar'26.
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2026 ,inter alia, to consider and approve To consider Un-Audited Financial ....
Rescheduled / Cancelled · 30 Mar 2026, 5:30 am
Supha Pharmachem Board Meeting for Q3 FY26 Results Postponed Again Supha Pharmachem has further postponed its board meeting to approve Q3 FY26 financial results, now rescheduled for 30th Mar'26. The meeting, originally set for 14th Feb'26, was delayed due to the non-availability of financial information from its overseas subsidiary in Singapore, which is required for the consolidated results. The agenda includes approving unaudited standalone and consolidated results for the quarter and nine months ended 31st Dec'25. The trading window remains closed for insiders since 1st Jan'26.
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2026 ,inter alia, to consider and approve unaudited standalone and consolidated ....
Rescheduled / Cancelled · 09 Mar 2026, 5:30 am
Supha Pharmachem Postpones Board Meeting for Q3 Results to March 9th Supha Pharmachem Ltd announced a further postponement of its Board Meeting to consider and approve unaudited standalone and consolidated results for the quarter ended 31st Dec'25. The meeting, originally scheduled for 14th Feb'26 and later moved to 25th Feb'26, is now rescheduled to 9th Mar'26. The delay is due to the non-availability of financial information from its overseas subsidiary in Singapore, which is required for finalising consolidated results. The trading window remains closed for insiders since 1st Jan'26.
Rescheduling on 25/02/2026
Intimation · 25 Feb 2026, 5:30 am
Supha Pharmachem Board Meeting Rescheduled to Feb 25, 2026 Supha Pharmachem has postponed its board meeting, originally scheduled for 14th Feb'26, to 25th Feb'26. The delay is due to the non-availability of financial information from its overseas subsidiary in Singapore, which is required for finalizing consolidated results. The rescheduled meeting will consider the unaudited standalone and consolidated financial results for the quarter and nine months ended 31st Dec'25. The trading window for insiders remains closed and will reopen 48 hours after the results are declared.
Demise of CS and Compliance Officer
Change in Management · 14 Feb 2026, 8:33 pm
Supha Pharmachem Announces Demise of Company Secretary Supha Pharmachem Limited reported the demise of its Company Secretary and Compliance Officer, Mr. Kapil Goplani, on 13th Jan'26. The company was officially informed on 14th Feb'26, as Mr. Goplani had been on leave for the past two months. The disclosure was made within 24 hours of intimation. The company is now in the process of appointing a successor to fill the key managerial personnel vacancy. Mr. Goplani had been in the role since 1st Jun'25.
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited Financial Results/Statements ....
Intimation · 14 Feb 2026, 5:30 am
Supha Pharmachem Board Meeting Scheduled to Review Q3 FY26 Results Supha Pharmachem Ltd (BSE: 539561) has scheduled a Board of Directors meeting on 14th Feb'26. The agenda includes the consideration and approval of the un-audited standalone and consolidated financial results for the third quarter and nine months ended 31st Dec'25. The trading window for insiders has been closed since 1st Jan'26 and will reopen 48 hours after the results are declared. This meeting is a key event for assessing the company's financial performance.
Company is pleased to informed that MCA has approved the change of name vide certificate of incorporation W.E.F. 15/12/2025 from REMEDIUM LIFECARE LTD. TO SUPHA PHARMACHEM LIMITED
Others (Uncategorized) · 15 Dec 2025, 5:03 pm
Remedium Lifecare Changes Name to Supha Pharmachem Limited Remedium Lifecare Ltd. (Scrip: 539561) has changed its name to Supha Pharmachem Limited, effective 15 Dec'25. The name change has been approved by the Ministry of Corporate Affairs, as per the certificate of incorporation issued on the same date. The company will now proceed with the name change application process with the BSE. This corporate action follows the company's intimation on 22 Sep'25 and is pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to Rs.862.34 Lakh
Press Release · 17 Nov 2025, 2:27 pm
Financial Results for Quarter and Half Year ended September 30, 2025
Financial Result · 14 Nov 2025, 8:11 pm
Board Meeting Outcome for The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter and Half year Ended September 30, 2025
Outcome · 14 Nov 2025, 8:03 pm
Remedium Lifecare Strengthens Leadership for Next-Phase Growth
Press Release · 10 Nov 2025, 5:42 pm
Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Unaudited Standalone and ....
Intimation · 14 Nov 2025, 5:30 am
Appointment
Others (Uncategorized) · 01 Nov 2025, 3:28 am
the Board in ite metting approved 1. Appointed Mr. Rambhajan Vishwakarma . 2. Appointed Mr. Vignesh Laxman Gawde . 3. Approved the Postal Ballot notices 4. The Board has reconstituted ....
Others (Uncategorized) · 01 Nov 2025, 3:26 am
Resignation of Mr. Mansoor Abdul Vahab
Change in Management · 30 Oct 2025, 4:35 am
Resignation of Mr. Dipesh Vaidya Non- Executive Independent Director
Change in Management · 07 Oct 2025, 4:16 am
e-voting results of AGM and scrutinizer Report of AGM held on 24.09.2025 through VC/OAVM
Annual General Meeting · 24 Sept 2025, 7:16 pm